Dagogo-Jack Ibiayi, Saltos Andreas, Shaw Alice T, Gray Jhanelle E
From the Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hematology/Oncology Fellowship Program, Moffitt Cancer Center, Tampa, FL; University of South Florida, Tampa, FL; Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL.
Am Soc Clin Oncol Educ Book. 2017;37:619-629. doi: 10.1200/EDBK_175197.
Lung cancer is a heterogeneous diagnosis that encompasses a spectrum of histologic and molecular subgroups. A paradigm shift favoring selection of treatment based on histologic and molecular makeup has positively affected prognosis for patients with metastatic lung cancer, with select patients experiencing durable responses to treatment. However, prognosis remains poor for the majority of patients. Furthermore, oncologists are increasingly faced with challenging dilemmas related to histopathologic and molecular characterization of tumors, both at diagnosis and during treatment. In this review, we focus on three particular challenges: (1) management of mixed histology tumors, a particularly aggressive group of lung cancers, (2) distinguishing multiple primary lung tumors from intrapulmonary metastases, and (3) incorporation of liquid biopsies into the diagnostic algorithm and subsequent follow-up of patients with advanced lung cancer. This review will summarize the existing literature and highlight the potential for molecular genotyping to help refine approaches to each of these challenges.
肺癌是一种异质性诊断,涵盖了一系列组织学和分子亚组。基于组织学和分子组成选择治疗方法的模式转变对转移性肺癌患者的预后产生了积极影响,部分患者对治疗产生了持久反应。然而,大多数患者的预后仍然很差。此外,肿瘤学家在诊断和治疗过程中越来越多地面临与肿瘤组织病理学和分子特征相关的具有挑战性的困境。在本综述中,我们关注三个特定挑战:(1)混合组织学肿瘤的管理,这是一组特别侵袭性的肺癌;(2)区分多个原发性肺肿瘤与肺内转移瘤;(3)将液体活检纳入晚期肺癌患者的诊断算法及后续随访。本综述将总结现有文献,并强调分子基因分型有助于改进应对这些挑战的方法的潜力。